Iksuda Therapeutics is a biotechnology company focussed on the development of a new generation of antibody drug conjugates (ADCs) targeting difficult-to-treat haematological and solid tumours. Iksuda’s pipeline of ADCs is centred on a portfolio of non-prodrug/prodrug DNA and protein alkylating payloads in combination with stable conjugation chemistries including its proprietary PermaLink® platform. The Company’s ADCs portfolio is designed to significantly improve the therapeutic index of this important modality and improve the outcomes for patients living with cancer.
View Top Employees from Iksuda Therapeutics| Website | http://www.iksuda.com |
| Employees | 37 (27 on RocketReach) |
| Founded | 2007 |
| Technologies |
JavaScript,
HTML,
PHP
+9 more
(view full list)
|
| Industry | Biotechnology Research, Drug Discovery, Biotechnology |
Looking for a particular Iksuda Therapeutics employee's phone or email?
Iksuda Therapeutics Questions
Ian Evetts is the Chief Business Officer of Iksuda Therapeutics.
27 people are employed at Iksuda Therapeutics.
Top Iksuda Therapeutics Employees
-
35+
-
22
-
31
-
22
-
ViewJenny Thirlway
Executive Director, Development Leadership at Iksuda Therapeutics
Newcastle upon Tyne, GB1 -
2
-
1
-
11
-
View
Simon Frost
CMC and Research Alliance Manager at Iksuda at Iksuda Therapeutics
Stoke-on-Trent, England, GB2 -
View
Justyna Mysliwy
Senior Director, Research at Iksuda Therapeutics
Northumberland, Northumberland, United Kingdom1
Related Companies
